Company: SXTPW
Filing Date: 2025-09-02
Form Type: DEFR14A
Source: 0001213900-25-082789
Chunk: 2

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-02
Form: DEFR14A
Chunk 2
---
 Delaware corporation (“Company,” “we,” “us” and “our”), will be held on October 8, 2025 at 12:00 p.m. (Eastern Time) via a live audio webcast over the telephone. You will be able to virtually attend the Annual Meeting over the telephone and ask questions during the Annual Meeting. We are holding the Annual Meeting for the following purposes, which are more fully described in the accompanying proxy statement:

| (1) | to elect five (5) directors to serve until the 2026 Annual Meeting                                                       
 of Stockholders and until their respective successors are duly elected and qualified (the “Director Election Proposal”); |

| (2) | to approve an amendment to the 60 Degrees Pharmaceuticals, Inc. 2022                                                       
 Equity Incentive Plan (the “2022 Plan”) to increase the number of shares of common stock available for issuance by 250,000 
 shares (the “2022 Plan Amendment Proposal”);                                                                               |

| (3) | to approve an amendment to our certificate of incorporation, as corrected                                                             
 (“Certificate of Incorporation”), to effect a reverse stock split of our common stock at a reverse stock split ratio                  
 ranging from 1:3 to 1:10 inclusive, as determined by our Board of Directors in its sole discretion (the “Certificate of Incorporation 
 Amendment Proposal”);                                                                                                                 |

| (4) | to ratify the selection by our Board of Directors                                   
 of RBSM LLP as our independent auditor for the fiscal year ending December 31, 2025 
 (the “Auditor Proposal”);                                                           |

| (5) | to approve adjourning the                                                                                                             
 Annual Meeting, if necessary, to solicit additional proxies in the event there are not sufficient votes in favor of the Director      
 Election Proposal, the 2022 Plan Amendment Proposal and the Certificate of Incorporation Amendment Proposal at the time of the Annual 
 Meeting (the “Adjournment Proposal”); and                                                                                             |

| (6) | to transact such other business as may properly come 
 before the meeting.                                  |

These items of business are more fully described in the proxy statement (“Proxy Statement”) accompanying this Notice of Annual Meeting of Stockholders (the “Notice”). We are not aware of any other business to come before the Annual Meeting. After careful consideration, the Board has determined that each proposal listed above is in the best interests of the Company and its stockholders and has approved each proposal. The Board recommends a vote